Current management of chronic kidney disease (CKD) in type 1 diabetes centres on
glycaemic control, renin–angiotensin system inhibition and optimisation of risk factors …

Background and aims The SGLT2-inhibitors significantly reduce heart failure hospitalization
and progression to end-stage kidney disease. An increase in hemoglobin/hematocrit is seen …

BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect
the kidneys and heart, but the underlying mechanism remains poorly understood …

Aims/hypothesis Glucagon-like peptide-1 receptor agonists (GLP-1ras) and sodium–glucose
cotransporter 2 inhibitors (SGLT2is) have shown kidney-protective effects. Improved kidney …

Introduction Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose
cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease …

OBJECTIVE Renin–angiotensin system (RAS) inhibitors decrease the urinary albumin to
creatinine ratio (UACR) but are ineffective in up to 40% of patients. We hypothesized that …

Importance The association between sodium-glucose transport protein 2 inhibitor (SGLT2i)
use and the incidence of acute kidney injury (AKI) remains controversial. The benefits of …

SGLT2i (sodium glucose transporter type 2 inhibitors) are pharmacological agents that act
by inhibiting the SGLT2, by reducing the renal plasma glucose threshold and inducing …

Thanks to technical advances in the field of medical imaging, it is now possible to study key
features of renal anatomy and physiology, but so far poorly explored due to the inherent …

Chronic kidney disease (CKD) in type 2 diabetes is a large and growing problem leading to
end-stage kidney disease, atherosclerotic cardiovascular disease, and heart failure (HF) …